A Novel Model for Human Atopic Dermatitis: Application of Repeated DNCB Patch in BALB/c Mice, in Comparison with NC/Nga Mice

Lee, Kyoung‐Sun; Jeong, Eui‐Suk; Heo, Seung‐Ho; Seo, Jin‐Hee; Jeong, Dong Seop; Choi, Yang‐Kyu

doi:10.5625/lar.2010.26.1.95

Cited by 32 publications

(36 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several sensitizers are recommended of which the commonly used are: i) ovalbumin; ii) microbial antigen (mite, Staphylococcus aurius); iii) chemical compounds (picryl chloride, oxazolone, trinitrochlorobenzene, 1-chloro-2,4-dinitrobenzene) (Lee et al, 2010). In the present visual experiment, we have shown step by step procedure of DNCB-induced mouse model of atopic dermatitis.…”

Section: Discussionmentioning

confidence: 64%

Mouse model of DNCB-induced atopic dermatitis

Hamad

Han

Rather

2017

Bangladesh J Pharmacol

View full text Add to dashboard Cite

Atopic dermatitis is a skin disease characterized by allergic skin inflammation, redness and itching. The animal model is necessary to find out new drugs. The DNCB-induced animal model of atopic dermatitis includes the following steps: 1) Selection of animals; 2) Shaving of dorsal skin; 3) Applying DNCB once in 24 hours for three days; 4) Monitoring the development of atopy on day 4 post DNCB application. Further, the efficacy of reference drug can be determined by applying on the atopy skin, depends on the nature and aim of the work.

show abstract

Section: Discussionmentioning

confidence: 64%

Mouse model of DNCB-induced atopic dermatitis

Hamad

Han

Rather

2017

Bangladesh J Pharmacol

View full text Add to dashboard Cite

show abstract

“…Interactions of genetic, environmental and immunological factors result in the initiation and progress of AD (Novak and Bieber, ). Although many possible mechanisms of AD have been researched and proposed, its aetiology remains unclear (Lee et al ., ). In addition, despite the many studies on biological and pharmacological activities of bee venom and melittin, the therapeutic effects of these two substances against AD‐related mechanisms remain unknown.…”

Section: Discussionmentioning

confidence: 97%

Therapeutic effects of bee venom and its major component, melittin, on atopic dermatitis in vivo and in vitro

Kim

et al. 2018

British J Pharmacology

View full text Add to dashboard Cite

Background and PurposeAtopic dermatitis (AD) is a multifactorial skin condition with complex interactions of innate and adaptive immune responses. There are several existing therapies for AD, including topical glucocorticosteroids, emollients, phototherapies, calcineurin inhibitors and immunosuppressants, such as cyclosporine A. Although these therapies reduce inflammation, they also cause serious side effects. Therefore, it is necessary to develop new therapeutic approaches for AD treatment without side effects. There are several studies on natural materials or toxins, such as herbs, ginseng extract and snake venom, for AD treatment. However, treatment of AD with bee venom and its major component, melittin has rarely been studied.Experimental ApproachEffects of bee venom and melittin were studied in a model of AD in vivo induced by 1‐chloro‐2,4‐dinitrobenzene (DNCB) in female Balb/c mice and in cultures of human keratinocytes, stimulated by TNF‐α/IFN‐γ. The potential pharmacological effects of bee venom and melittin on these in vivo and in vitro AD‐like skin disease models were studied.Key ResultsBee venom and melittin exhibited potent anti‐atopic activities, shown by decreased AD‐like skin lesions, induced by DNCB in mice. In vitro studies using TNF‐α/IFN‐γ‐stimulated human keratinocytes showed that bee venom and melittin inhibited the increased expression of chemokines, such as CCL17 and CCL22, and pro‐inflammatory cytokines, including IL‐1β, IL‐6 and IFN‐γ, through the blockade of the NF‐κB and STAT signalling pathways.Conclusions and ImplicationsOur results suggest that bee venom and melittin would be suitable for epicutaneous application, as topical administration is often appropriate for the treatment of AD.

show abstract

“…Furthermore, taking steroid drugs continuously for prolonged periods of time leads to severe side effects such as blood disorders, irregular heartbeat, and psychological interference (22). Accordingly, In this study, we evaluated the anti-AD effects of CRT using a DNCB-induced AD mouse model, which is typically used for studying the pathogenesis of AD (4). Topical application of CRT attenuated ear swelling induced by DNCB.…”

Section: Discussionmentioning

confidence: 99%

“…In most cases, patients with AD are treated with synthetic steroids. However, many clinical reports have warned that long-term use of synthetic steroids may result in side effects such as additional infections, gastrointestinal ulcers, osteoporosis, and insomnia (3)(4)(5). Therefore, the identification of novel anti-allergic naturally-derived agents from herbs and medicinal plants with less side effects are required for AD treatment.…”

Section: Introductionmentioning

confidence: 99%

Cryptotanshinone inhibits IgE‑mediated degranulation through inhibition of spleen tyrosine kinase and tyrosine‑protein kinase phosphorylation in mast cells

et al. 2018

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a type of chronic skin inflammation and one of the most common relapsing allergic diseases, which presents with a severe rash and itchy skin lesions. The pathogenesis of AD is primarily associated with hyper‑activated mast cells, which makes them an effective treatment target. After cross‑linking the antigen/immunoglobulin (Ig) E complex binds to its high affinity receptor FcεRl on the surface of mast cells. The cells subsequently secrete excessive pro‑inflammatory mediators, including histamine and cytokines, which lead to pruritus and immune cell infiltration in the skin lesions. The present study screened natural compounds that have an inhibitory effect on IgE/antigen‑mediated secretory activity. It was revealed that cryptotanshinone (CRT), a natural compound extracted from Salvia miltiorrhiza Bunge, had inhibitory effects on the IgE/antigen complex. The underlying mechanism by which CRT exerted an anti‑allergy/inflammatory function was investigated using rat basophilic leukaemia (RBL) cells for degranulation assays and a 1‑chloro‑2,4‑dinitrobenzene (DNCB)‑induced AD Balb/c mouse model for in vivo study. CRT effectively mitigated the secretion of pro‑inflammatory cytokines, including tumor necrosis factor‑α and interleukin 1β, as well as immune cell infiltration into skin lesions in a mouse model of AD‑like skin disease induced by dinitrochlorobenzene. The inhibitory effect of CRT on IgE‑mediated mast cell degranulation was mediated by the inhibition of tyrosine kinase‑dependent degranulation signalling pathways involving spleen tyrosine kinase and Lyn. The present study revealed CRT as an inhibitor of mast cell degranulation. Therefore, CRT may be considered for development as a therapeutic drug to treat IgE‑mediated skin diseases.

show abstract

A Novel Model for Human Atopic Dermatitis: Application of Repeated DNCB Patch in BALB/c Mice, in Comparison with NC/Nga Mice

Cited by 32 publications

References 35 publications

Mouse model of DNCB-induced atopic dermatitis

Mouse model of DNCB-induced atopic dermatitis

Therapeutic effects of bee venom and its major component, melittin, on atopic dermatitis in vivo and in vitro

Cryptotanshinone inhibits IgE‑mediated degranulation through inhibition of spleen tyrosine kinase and tyrosine‑protein kinase phosphorylation in mast cells

Contact Info

Product

Resources

About